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AVIDIN AS A MODEL FOR CHARGE DRIVEN TRANSPORT INTO
CARTILAGE: RELEVANCE TO OSTEOARTHRITIS DRUG DELIVERY
A.G. Bajpayee, A.J. Grodzinsky. MIT, Cambridge, MA, USA
Purpose: There is an unmet need for effective ways to locally and safely
introduce DMOADs into cartilage, to minimize systemic adverse effects
and to increase drug speciﬁcity for targets in the tissue. Several studies
have focused on drug-encapsulating polymeric particles whose effec-
tiveness depends on their ability to enter the dense cartilage ECM and to
be retained over time. Our recent studies using solutes having a wide
size range (1-15nm diameter) revealed that nanoparticles with diam-
eter<10nm could penetrate into and diffuse throughout cartilage while
larger solutes became trapped within the superﬁcial zone. We now
conﬁrmed this size limitation using NeutrAvidin, a globular protein
(diamw7nm, 60kDa, electrically neutral). While nanoparticle transport
is size and shape dependent, surface charge can greatly affect their
binding within ECM. Therefore, we compared the binding and transport
properties of NeutrAvidin to Avidin, a highly positively charged protein
of similar MW and size.
Methods: Cartilage disks (6mm diam, 1mm thick) were harvested from
the femoropatellar grooves of 1-2 week old bovine calf knee joints.
Transport and binding properties of FITC-labeled NeutrAvidin (pIw7)
and Avidin (pIw10.5) were measured. A transparent PMMA transport
chamber (Fig 1F) allowed diffusion of solutes from only one side
(superﬁcial zone) of the disk. Half-cylindrical disks were placed within
slots in the middle of the chambers. The chamber side facing the
superﬁcial zone was ﬁlled withw45ml solution of solute in 1X-PBS; the
other side was ﬁlled with 1X PBS. The chamber was placed on a low-
speed rocker inside a 37-deg incubator. At selected times, samples were
removed from the chamber and gently rinsed. A full-thickness slice was
cut from the center of the sample and imaged using a confocal micro-
scope at 10X magniﬁcation. For desorption studies, the solute solution
was removed from the chamber and replaced with 1X or 10X PBS.ĂResults: Figs 1A, B, C along with their ﬂuorescence intensity-vs-depth
graphs show increasing penetration of NeutrAvidin at 1, 2 and 4 days
from the superﬁcial zone (denoted by arrows). Fluorescence intensity is
plotted vs distance from the left edge of the images. Figs. 1D, E show
explants after 24h desorption of NeutrAvidin in 1X and 10X PBS
respectively, suggesting that most NeutrAvidin diffused out similarly by
24h. In contrast, Avidin completely penetrated and diffused throughout
the cartilage within 24h (Fig 2A). While some Avidin diffused out of the
explants after 24h in 1XPBS (Fig 2B), signiﬁcantly more Avidin diffused
out in 10X PBS. Explants within the chamber (Fig. 1F) show visual
evidence of signiﬁcantly higher uptake of Avidin compared to Neu-
trAvidin in 24h (i.e., cartilage ﬂuorescence staining).
Conclusions: Our results suggest that the transport and binding of
Avidin into bovine cartilage is driven by strong electrostatic interac-
tions. Despite their similar sizes, Avidin penetrated through the full
thickness (1mm) of cartilage in 24h, while it took 4 days for NeutrAvidin
to penetrate half the thickness. A 400-times greater uptake was
measured for Avidin compared to NeutrAvidin in 24h. NeutrAvidin
diffused out in both 1X and 10X PBS while Avidin remained bound in 1X
PBS but diffused out in 10X PBS. We hypothesize that Avidin binds to
negatively charged GAG chains in the cartilage: both Avidin and Neu-
trAvidin exhibited identical absorption and desorption properties in
GAG-depleted cartilage explants (data not shown), further conﬁrming
the effects of electrostatic interactions. Using principles of Donnan
equilibrium, we calculated a net charge of approx. +15 on Avidin. This
work suggests that polymeric particles mimicking the structure of
Avidin (i.e.,w7nm diameter with high positive charge) might facilitate
higher and faster uptake into cartilage from the surrounding synovial
ﬂuid, and also bind within the tissue, thereby providing sustained local
drug delivery.567
STATINS AND FIBRATES DO NOT AFFECT DEVELOPMENT OF
SPONTANEOUS OSTEOARTHRITIS IN STR/ORT MICE
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Osch y. y Erasmus Univ. Med. Ctr., Rotterdam, The Netherlands; zUniv. of
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Purpose: Osteoarthritis (OA) has been associated with the metabolic
syndrome and is characterized by inﬂammation in joint tissues. Since
statins and ﬁbrates are potentially capable of decreasing inﬂammatory
processes in the joint as well as improving the metabolic proﬁle of
patients, theymight be considered as potential drugs for preventing OA.
To investigate whether OA development in the tibiofemoral joint can be
prevented or delayed by statins and/or ﬁbrates, we orally administered
these drugs in different doses to STR/ORT mice that develop sponta-
neous OA.
Methods: 8 weeks old male STR/Ort mice (n¼72) were divided into 6
experimental groups (n¼12 per group). One group received reference
diet (CTR) and the other groups received reference diet mixed with two
different dosages of simvastatin (40 mg/kg body weight (BW)/day or 80
mg/kg BW/day) or fenoﬁbrate(100 mg/kg BW/day or 200 mg/kg BW/
day) or a combination of simvastatin (40 mg/kg BW/day) and fenoﬁ-
brate (100 mg/kg BW/day). Mice were euthanized after 16 weeks of
treatment at the age of 6 months. Serum measurement of cholesterol
(Chol), triglyceride (TG) and amyloid A (SAA) was performed. Knee
cartilage damage was evaluated by histology using the OARSI scoring
method.
Results: Fenoﬁbrate treated mice gained less BW compared to other
mice. Serum Chol and TG were not signiﬁcantly different between the
groups at 16 weeks. SAAwas increased in the CTR group after 16 weeks.
Simvastatin treatment did not decrease SAA. Fenoﬁbrate treatment
reduced SAA at 16 weeks to the level before start of treatments. Carti-
lage damage was most profound in the medial compartment of the
joint. No signiﬁcant difference in OA score was detected between the
different groups, although a trend to a lower OA score was seen in the
80 mg/kg bodyweight/day simvastatin treated group. No correlation
was found between BW, serum Chol, serum TG, SAA and OA scores.
Conclusions: In our study, statin and ﬁbrate treatment did not signif-
icantly decrease the development of OA cartilage damage in STR/Ort
mice at the age of 6 months. Our results indicate that ﬁbrate treatment
could prevent the increase in BW and SAA. However, BW and SAA are
not correlated with OA cartilage damage in the STR/Ort mice.
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DICLOFENAC SUBMICRON PARTICLE CAPSULES DEMONSTRATE
EARLY AND SUSTAINED ACUTE PAIN RELIEF IN A PHASE 3 STUDY
IN PATIENTS FOLLOWING BUNIONECTOMY SURGERY
C. Argoff y, S. Silberstein z, A. Gibofsky x, S. Daniels k, S. Jensen {, C.
Young {. yAlbany Med. Coll., Albany, NY, USA; z Thomas Jefferson Univ.,
Philadelphia, PA, USA; xHosp. for Special Surgery, New York, NY, USA;
k Premier Res. Group, Ltd, Austin, TX, USA; { Iroko Pharmaceuticals, LLC,
Philadelphia, PA, USA
Purpose: Early management of acute pain may impact the severity and
duration of pain. NSAIDs are utilized to treat acute pain but have the
potential for serious dose-related gastrointestinal, cardiovascular, and
renal adverse events (AEs). Investigational submicron particle NSAIDs
using proprietary SoluMatrix technology are being evaluated to assess
the potential to provide effective pain relief at lower doses than
currently available oral NSAIDs. In a Phase 1 study, diclofenac submi-
cron particle capsules 35 mg achieved an early time to maximum
concentration, a similar maximum concentration, and lower systemic
drug exposure compared with diclofenac potassium immediate-release
tablets. In a Phase 2 study, diclofenac submicron particle capsules (18
and 35 mg) provided effective analgesia and were generally well-
tolerated in a validated post-surgical model of mild to moderate pain.
We evaluated the analgesic efﬁcacy of diclofenac submicron particle
capsules in a post-surgical model of moderate to severe pain.
Methods: This Phase 3 multi-center, double-blind study enrolled 428
patients 18-65 years of age who underwent a primary, unilateral ﬁrst
metatarsal bunionectomy with osteotomy and ﬁxation under regional
anesthesia. Patients experiencing a pain intensity rating of 40mm on
a 100mm visual analog scale (VAS) were randomized to receive diclo-
fenac submicron particle capsules (18 or 35mg; TID), celecoxib (400mg
loading dose, then 200mg BID), or placebo. The primary endpoint was
the summed pain intensity difference measured by VAS over 48 hrs
(VAS SPID-48). Secondary endpoints included the VAS pain intensity
difference (VAS PID) at various time points versus placebo.
Results: As presented recently for the primary endpoint (mean VAS
SPID-48), diclofenac submicron particle 35mg (524; P<0.001) and 18mg
(393; P¼0.01) and celecoxib (391; P¼0.011) demonstrated signiﬁcant
pain control compared with placebo. Some pain relief (mean VAS PID)
was apparent in the diclofenac submicron particle 35mg (4.52) group at
30min in contrast to the placebo (0.12) group. Pain control increased
over time for all active treatment groups. At 4h after dose administra-
tion, diclofenac submicron particle 35mg provided better pain control
(VAS PID) versus placebo (P¼0.025; Figure). At 5h after study entry,
signiﬁcant pain control was noted in the diclofenac submicron particle
35mg (9.43; P¼0.002), 18mg (8.35; P¼0.009), and celecoxib (6.62;
P¼0.032) treatment groups versus placebo (2.30; Figure).Overall, the
most frequent treatment-emergent adverse events were localized post-
procedural edema (32.7%, 140/428), nausea (29.7%, 127/428), headache
(12.9%, 55/428), and dizziness (11.7%, 50/428).
ĂConclusions: Lower-dose, submicron particle diclofenac demon-
strated better pain control at 48h (VAS SPID-48) with evidence of
analgesia as early as 30 min after administration compared with
placebo, and was generally well tolerated. These results suggest that
diclofenac submicron particle capsules are a potentially promising
therapeutic option for acute pain.569
MANAGEMENT OF PATIENTS WITH KNEE OSTEOARTHRITIS BEFORE
AND AFTER THE PHILIPPINE CLINICAL PRACTICE GUIDELINE FOR
KNEE OSTEOARTHRITIS
G.Z. Racaza, E.G. Penserga. Philippine Gen. Hosp., Taft Avenue, Manila,
Philippines
Purpose: We aim to review changes in physicians’ practice on the
management of osteoarthritis (OA) before and after the publication of
the Philippine Rheumatology Association (PRA) Clinical Practice
Guidelines (CPG) for knee OA in year 2010. Major highlights of the CPG
were advocacy of paracetamol as ﬁrst-line pharmacologic therapy fol-
lowed by tramadol, good evidence for usage of glucosamine sulfate,
limitation of NSAIDs usage, and emphasis on rehabilitation and lifestyle
modiﬁcation/advice.
Methods: This study reviewed clinical charts of patients diagnosed
with primary OA (American College of Rheumatology criteria) in the
Philippine General Hospital Arthritis Clinic from January to December
2009 and January to December 2011. Data regarding conventional
management (non-pharmacologic and pharmacologic) and comple-
mentary/alternative therapies on the ﬁrst visit were extracted.
Continuous data were described using means and standard deviations
while nominal data were described using frequencies and percentages.
T-test for two proportions were used to compare use of different
pharmacologic and alternative treatment pre- and post- CPG. P-value
less than 0.05 were considered signiﬁcant.
Results: One hundred eleven patients were included in the study (60
from 2009 and 51 from 2011). Mean age of symptom presentation and
diagnosis were 59.7 years (SD: 10.3 years) 63.2 years (SD: 9.9 years),
respectively. Majority (81.08%) were females. Mean BMI was 26.5 kg/m2
(SD: 5.03), considered obese stage I. The most common presentation
was knee pain (69.8%), majority (76.48%) of which were bilateral. There
were no signiﬁcant differences (p-value 0.723) between the mean age
between pre- (mean 59.3 years; SD 1.5 years) and post-CPG patients
(mean 60.1 years; SD 1.3 years). Likewise, there were no signiﬁcant
differences in sex (p-value 0.2529) and proportion of dyspeptics (p-
value 0.4760). Mean BMI is higher among pre-CPG patients (mean 27.9;
SD 0.78) compared to post-CPG (mean 25.69; SD 0.56) and the result is
statistically signiﬁcant (p-value 0.03). There were statistically more
patients post-CPG who had Kellgren Lawrence score of 2 compared to
pre-CPG patients. The two populations had no signiﬁcant difference
across the rest of the scores. The use of paracetamol is signiﬁcantly
higher among post-CPG patients (54/60, 90% vs pre-CPG 33/51, 64.71%;
p-value 0.0013) but the use of tramadol before and after CPG publica-
tion is not statistically signiﬁcant (p-value 0.1119). Use of NSAID (COX-1
inhibitor) and COX-2 inhibitors was signiﬁcantly lower after the CPG
publication [(5/60, 8.33% vs pre-CPG 17/51, 33.33%; p-value 0.013) and
(6/60, 10.17% vs pre-CPG 25/51, 49.02%; p-value 0.000), respectively].
Glucosamine sulfate use was slightly higher post-CPG (31/51, 51.67%)
compared to pre-CPG (25/60, 49.02%) but this difference was not
statistically signiﬁcant (p-value 0.7810). Use of non-pharmacologic
interventions was signiﬁcantly higher post-CPG (49/60, 81.67%
compared to pre-CPG 12/51, 23.53%, p value 0.0000).
Conclusion: The published CPG by the PRA signiﬁcantly changed the
physicians’ management of patients with OA. Whether it has impacted
the patients’ symptoms, quality of life and overall satisfaction, however,
remains to be determined and can be the subject of studies in the near
future.570
A SINGLE INTRA-ARTICULAR INJECTION WITH IL-4 PLUS IL-10
AMELIORATES BLOOD-INDUCED CARTILAGE DEGENERATION IN
HAEMOPHILIC MICE
L. van Vulpen, M.E. van Meegeren, G. Roosendaal, K. Coeleveld, L.
Nieuwenhuizen, S.C. Mastbergen, F.P. Lafeber. UMC Utrecht, Utrecht,
The Netherlands
Purpose: Exposure of joint cartilage to blood can occur after joint
trauma, during or after major joint surgery, or due to hemophilia. This
ultimately leads to joint damage, both by direct effects of blood on
cartilage and via synovial inﬂammation (Lafeber et al., Haemophilia
2008). The cytokines interleukine (IL)-4 and IL-10 are known as
modulatory cytokines. A combination of IL-4 plus IL-10 protects against
blood-induced cartilage damage in vitro (van Meegeren et al., Osteoar-
thritis & Cartilage 2012). It has been hypothesized that the combination
